Opko: Why I Am Cautiously Bullish
- OPK stock is beaten down at the current time.
- However, it has considerable potential from marketed and upcoming products.
- Balancing pros and cons together, I see reasons to be bullish here.
- This is an abridged version of the type of research that will be available to subscribers of the Total Pharma Tracker (TPT).
S. Mitra, MBA (ISB) with inputs from Dr UK Maiya, MD
Opko (OPK) has 5 things going for it - its beaten down stock price, on-the-surface mixed earnings with a possible positive explanation, strong Rayaldee uptake, Dr Philip Frost’s involvement, and a moderately strong pipeline. On the flipside, the company has low cash balance compared to its market cap. Overall, I am cautiously bullish OPK.
The full post is available to investor members only. Subscribe here.